Work

Author response: Combined ALK and MDM2 inhibition increases antitumor activity and overcomes resistance in human ALK mutant neuroblastoma cell lines and xenograft models

Year: 2017

Type: peer-review

Abstract: The combination of ceritinib with CGM097 demonstrates remarkable antitumor activity in TP53 wild-type neuroblastoma models with ALK aberrations and is able to overcome the resistance acquired during ceritinib treatment.

DOI: 10.7554/elife.17137.017

Authors: Hui Qin Wang, Ensar Halilovic, Xiaoyan Li, Jinsheng Liang, Yichen Cao, Daniel P Rakiec, David A Ruddy, Sebastien Jeay, Jens U Wuerthner, Noelito Timple, Shailaja Kasibhatla, Nanxin Li, Juliet A Williams, William R Sellers, Alan Huang, Fang Li

Institutions: Novartis (Switzerland), Novartis Institutes for BioMedical Research, Genomics Institute of the Novartis Research Foundation

Language: English

Topic: Neuroblastoma Research and Treatments

Subfield: Neurology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4253438477

Cites:

Cited by:

Related to: 10